186 related articles for article (PubMed ID: 25002857)
1. Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.
Koizumi H; Goto S; Okita S; Morigaki R; Akaike N; Torii Y; Harakawa T; Ginnaga A; Kaji R
Front Neurol; 2014; 5():98. PubMed ID: 25002857
[TBL] [Abstract][Full Text] [Related]
2. Evidence for central antispastic effect of botulinum toxin type A.
Matak I
Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
[TBL] [Abstract][Full Text] [Related]
3. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
Caleo M; Spinelli M; Colosimo F; Matak I; Rossetto O; Lackovic Z; Restani L
J Neurosci; 2018 Nov; 38(48):10329-10337. PubMed ID: 30315128
[TBL] [Abstract][Full Text] [Related]
4. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.
Marinelli S; Vacca V; Ricordy R; Uggenti C; Tata AM; Luvisetto S; Pavone F
PLoS One; 2012; 7(10):e47977. PubMed ID: 23110146
[TBL] [Abstract][Full Text] [Related]
5. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system.
Mazzocchio R; Caleo M
Neuroscientist; 2015 Feb; 21(1):44-61. PubMed ID: 24576870
[TBL] [Abstract][Full Text] [Related]
6. Long-distance retrograde effects of botulinum neurotoxin A.
Antonucci F; Rossi C; Gianfranceschi L; Rossetto O; Caleo M
J Neurosci; 2008 Apr; 28(14):3689-96. PubMed ID: 18385327
[TBL] [Abstract][Full Text] [Related]
7. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
8. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A).
Restani L; Antonucci F; Gianfranceschi L; Rossi C; Rossetto O; Caleo M
J Neurosci; 2011 Nov; 31(44):15650-9. PubMed ID: 22049408
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type a antinociceptive activity in trigeminal regions involves central transcytosis.
Nemanić D; Mustapić M; Matak I; Bach-Rojecky L
Eur J Pharmacol; 2024 Jan; 963():176279. PubMed ID: 38123005
[TBL] [Abstract][Full Text] [Related]
10. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
11. Botulinum neurotoxin type A subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model.
Itakura M; Kohda T; Kubo T; Semi Y; Nishiyama K; Azuma YT; Nakajima H; Kozaki S; Takeuchi T
J Vet Med Sci; 2014 Aug; 76(8):1189-93. PubMed ID: 24849052
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin's axonal transport from periphery to the spinal cord.
Matak I; Riederer P; Lacković Z
Neurochem Int; 2012 Jul; 61(2):236-9. PubMed ID: 22580329
[TBL] [Abstract][Full Text] [Related]
13. The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats.
Cornet S; Périer C; Wagner S; Andriambeloson E; Pouzet B; Kalinichev M
Toxicon X; 2020 Sep; 7():100041. PubMed ID: 32550595
[TBL] [Abstract][Full Text] [Related]
14. Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.
Moritz MS; Tepp WH; Inzalaco HN; Johnson EA; Pellett S
Toxicon; 2019 Sep; 167():20-28. PubMed ID: 31181297
[TBL] [Abstract][Full Text] [Related]
15. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
[TBL] [Abstract][Full Text] [Related]
16. Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson's disease model.
Itakura M; Kohda T; Kubo T; Semi Y; Azuma YT; Nakajima H; Kozaki S; Takeuchi T
Biochem Biophys Res Commun; 2014 May; 447(2):311-4. PubMed ID: 24713302
[TBL] [Abstract][Full Text] [Related]
17. Lasting Peripheral and Central Effects of Botulinum Toxin Type A on Experimental Muscle Hypertonia in Rats.
Šoštarić P; Vukić B; Tomašić L; Matak I
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232926
[TBL] [Abstract][Full Text] [Related]
18. Beyond neuromuscular activity: botulinum toxin type A exerts direct central action on spinal control of movement.
Šoštarić P; Matić M; Nemanić D; Lučev Vasić Ž; Cifrek M; Pirazzini M; Matak I
Eur J Pharmacol; 2024 Jan; 962():176242. PubMed ID: 38048980
[TBL] [Abstract][Full Text] [Related]
19. Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection.
Cai BB; Francis J; Brin MF; Broide RS
Neuroscience; 2017 Jun; 352():155-169. PubMed ID: 28389376
[TBL] [Abstract][Full Text] [Related]
20. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
